Compare Amphastar Pharmaceuticals Inc (AMPH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs BIO-TECHNE Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.41 (market cap $826.08M), while BIO-TECHNE Corp trades at $71.26 (market cap $11.11B). The key difference: BIO-TECHNE Corp is far larger — about 13.4× Amphastar Pharmaceuticals Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TECH | |
|---|---|---|
Market Cap | $826.08M | $11.11B |
Sector | Health | Health |
52-Week High | $30.81 | $71.38 |
52-Week Low | $16.87 | $43.31 |
Enterprise Value | $1.22B | $11.19B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Bio-Techne (TECH) trades at $71.30, up 0.21% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, while fundamentals reveal high valuation multiples (P/E 101.84) amid declining net margins (6.01% in 2025). Recent earnings were mixed with one beat and two misses in the last four quarters. Cash flow improved in 2026 projections, and the balance sheet remains solid with $152.86M cash.
The pending acquisition at $73.00 per share limits near-term upside but provides a floor. Risks include shareholder litigation questioning the deal's fairness and execution volatility. Analyst consensus is evenly split between Buy and Hold, with the price target slightly below current levels. The primary opportunity is the acquisition premium, while fundamental weakness in profitability poses a risk if the deal falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
